{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 41,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 36,
  "notes": "Includes detailed clinical trial enrollment metrics by dose cohort and patient population.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/17",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "PHASE 1 OBJECTIVES: Selection of RP2D and, if applicable, MTD (primary); Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c55ac6b4-a282-4da6-8afe-51c83c1c1d66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.06,
        "y": 0.36
      },
      "kind": "list",
      "text": "PATIENT POPULATION: Advanced solid tumors harboring ALK fusion or activating mutation; Patients with NSCLC: ≥ 1 prior 2G or 3G ALK TKI; ≤ 2 prior chemotherapies/immunotherapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e47383aa-0621-43e2-8b33-ae3ed76142e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "PHASE 1 DOSE-ESCALATION Ongoing at global sites across sites in North America, Europe, Asia and Australia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292c03a2-6d2b-4449-afa8-bd36917d1c58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.39,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1abde67c-be1e-4323-a21e-3455f7849417",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.39,
        "y": 0.28
      },
      "kind": "table",
      "text": "Enrollment table showing NVL-655 dose cohorts (15mg to 200mg) across BOIN Dose-Escalation, Expansion, and NSCLC Response-Evaluable populations.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "973fdc2e-0dca-44f6-953a-88b350b31609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKove-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-655 in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aeb9f908-7306-4c52-9745-2caea2535654",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}